Dermatologic toxicity of chemotherapeutic agents.
Due to its high metabolic rate, skin represents one of the major target organs of chemotherapy-associated toxicity. Reactions range from common, nonspecific exanthematous eruptions to rare but distinctive cutaneous lesions that may not become apparent until a drug transitions from clinical trials to widespread oncologic use. The challenge of the physician is to recognize reaction patterns that reflect a drug reaction, identify a likely causative drug, and determine whether the reaction is a dose-limiting toxicity. This review will focus on the cutaneous side effects of the newer classes of chemotherapy drugs, including targeted monoclonal antibody therapy and small molecule inhibitors.
Payne
Aimee S
AS
Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. aimee.payne@uphs.upenn.edu
James
William D
WD
Weiss
Raymond B
RB
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003937:Diagnosis, Differential; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D012871:Skin Diseases / Q000139:chemically induced*
D000970:Antineoplastic Agents